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Background: Susac syndrome (SuS) is a rare disorder thought to be caused by autoimmune-mediated occlusions
of microvessels in the brain, retina and inner ear leading to central nervous system (CNS) dysfunction, visual
disturbances due to branch retinal artery occlusions (BRAO), and hearing deficits. Recently, a role for anti-endothelial
cell antibodies (AECA) in SuS has been proposed.
Objectives: To report the clinical and paraclinical findings in the largest single series of patients so far and to
investigate the frequency, titers, and clinical relevance of AECA in SuS.
Patients and methods: A total of 107 serum samples from 20 patients with definite SuS, 5 with abortive forms of
SuS (all with BRAO), and 70 controls were tested for AECA by immunohistochemistry employing primate brain
tissue sections.
Results: IgG-AECA >1:100 were detected in 25% (5/20) of patients with definite SuS and in 4.3% (3/70) of the
controls. Median titers were significantly higher in SuS (1:3200, range 1:100 to 1:17500) than in controls
(1:100, range 1:10 to 1:320); IgG-AECA titers >1:320 were exclusively present in patients with SuS; three controls had
very low titers (1:10). Follow-up samples (n = 4) from a seropositive SuS patient obtained over a period of 29 months
remained positive at high titers. In all seropositive cases, AECA belonged to the complement-activating IgG1
subclass. All but one of the IgG-AECA-positive samples were positive also for IgA-AECA and 45% for IgM-AECA. SuS
took a severe and relapsing course in most patients and was associated with bilateral visual and hearing
impairment, a broad panel of neurological and neuropsychological symptoms, and brain atrophy in the majority of
cases. Seropositive and seronegative patients did not differ with regard to any of the clinical or paraclinical
parameters analyzed.
Conclusions: SuS took a severe and protracted course in the present cohort, resulting in significant impairment.
Our finding of high-titer IgG1 and IgM AECA in some patients suggest that humoral autoimmunity targeting the
microvasculature may play a role in the pathogenesis of SuS, at least in a subset of patients. Further studies are
warranted to define the exact target structures of AECA in SuS.
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Susac syndrome (SuS) is a rare disorder that is thought
to be caused by autoimmune-mediated occlusions of
microvessels in the brain, retina and inner ear [1] which
lead to a characteristic clinical triad of central nervous
system (CNS) dysfunction, visual disturbances and hearing
deficits [1-5]. Typical findings in patients with SuS include
branch retinal artery occlusions (BRAO) detectable on
retinal fluorescein angiography, characteristic callosal le-
sions on cranial MRI, and evidence of sensorineural hear-
ing loss [1,6]. The three index events defining SuS may
occur simultaneously or, more often, successively. The
disease may be monophasic or may follow a relapsing
or a chronic-progressive course.
The exact prevalence of SuS is unknown but is consid-
ered to be low; since the syndrome was first described in
1973 only about 300 patients have been reported worldwide
[1]. Accordingly, most of our current knowledge on SuS is
based on case reports or small case series, only very few of
which have included more than four patients [1].
Although spontaneous recovery and long-term remission
have been described, many patients respond to immuno-
suppressive agents, suggesting a possible autoimmune
pathogenesis [1,5,7]. A role for anti-endothelial cell
antibodies (AECA) in the pathogenesis of SuS was pro-
posed by Susac and co-workers in two review articles
in 2007 with reference to unpublished data [7,8]. However,
no original studies had been published by then to substan-
tiate this claim. When examining the only serum samples
from a patient with SuS regularly seen at our center at that
time, we indeed found evidence of an anti-endothelial
humoral immune response [9], in keeping with those
anecdotal reports. However, it remained unknown whether
AECA are a common phenomenon in SuS or whether that
was an isolated finding. A more recent study seems to
confirm the presence of AECA in SuS, but its results are
challenged by a number of methodological issues [10].
Here, we provide a summary of the most important
clinical and paraclinical findings associated with SuS from
one of the largest single cohorts of patients with SuS stud-
ied to date. In addition, we present data on the frequency,
titers and clinical relevance of AECA in SuS.
Patients and methods
Twenty-five patients with SuS and 70 controls, comprising
25 patients with multiple sclerosis (MS) (relapsing remitting
MS in 18, secondary progressive MS in 5, and primary
progressive MS in 2), 25 patients with connective tissue
disorders (CTD) with CNS involvement (systemic lupus
erythematosus (SLE) in 17, Sjögren syndrome (SS) in 1,
SLE and secondary SS in 1, Sharp syndrome in 5, and
scleroderma in 1) and 20 healthy controls (HC), were
analyzed for serum AECAs using a tissue-based indirect
immunofluorescence assay (IFA) [11]. Patients with SuSwere further stratified according to clinical, fluorescence
angiographic and MRI findings: While all patients in
group I (n = 20) had encephalopathy, hearing loss and
visual disturbances (‘complete SuS’), group II consisted
of patients (n = 5) in whom only two of the three typical
sites (brain, retina, inner ear) were affected but in whom
a diagnosis of SuS was likely due to the presence of
BRAO (‘limited SuS’). In addition, 12 follow-up samples
from 7 patients with definite SuS were available, adding
up to a total number of 107 samples tested, including 37
from patients with SuS.
All patients and controls were of Caucasian origin
(countries of origin are given in Table 1). The sex ratio (m:f)
was 1:2.6 in the SuS group (1:3 in the definite SuS subgroup)
and 1:3.4 in the control group (P= n.s.). The median age at
blood sampling was 32 years in the SuS group and 35 years
in the control group (P =n.s.) (Table 1).
All serum samples were stored at −80°C until testing.
The median time between SuS onset and blood sampling
was 5 years (range 0 to 18), and the median time between
the most recent SuS attack and blood sampling was
39.5 months (range 0 to 165). While 20 samples were
taken from untreated patients, 15 were taken during pe-
riods of active immunomodulatory or immunosuppressive
treatment; in 2 cases the exact treatment status at the time
of blood sampling was unknown. A total of 35.1% (13/37)
of samples were obtained during phases of active disease.
All patients with SuS had been treated at some point in
time, most commonly with platelet aggregation inhibitors
or anticoagulants (acetylsalicylic acid in 17, clopidogrel in
1, dipyridamole in 1, and fondaparinux in 1). Five patients
were treated with nimodipine and 1 with losartan. Immu-
nomodulatory (IM) and immunosuppressive (IS) treat-
ments used at some point in time included steroids in 18
patients, cyclophosphamide in 10, intravenous immuno-
globulins in 9, mycophenolate mofetil in 6, azathioprine in
4, and methotrexate in 2; overall, 23/25 patients (92%) had
received IM and/or IS treatments at least once.
Antibodies to CNS tissue were analyzed by indirect
immunofluorescence on adult primate (Macaca mulatta),
rat, and mouse cerebellum cryosections (Euroimmun,
Luebeck, Germany) as described [9,11,12]. Briefly, unfixed
or fixed cryosections (10% formalin for 4 min and 3-
[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS) 1% in PBS for another 4 min), respectively,
were blocked with 10% goat serum and subsequently
incubated with patient serum for 1 h. Human IgG, IgM
and IgA binding to CNS tissue were detected by the use
of prediluted polyclonal goat anti-human IgG, anti-
human IgM, or anti-human IgA, respectively, conju-
gated to fluorescein isothiocyanate (FITC) (Euroimmun).
Sections were mounted using ProLongGold mounting
medium (Invitrogen, Darmstadt, Germany) containing
4′,6-diamidino-2-phenylindole (DAPI; 1:1000). Each
Table 1 Epidemiological data from the total cohort and disease and control subgroups
Subjectsa Samples Median age (range) Sex (m:f)
All 90 90 33 (16 to 79) 1:3.1
SuS 25 37 32 (19 to 62) P = n.s.b,d 1:2.6 P = n.s.c,d
Definitive SuS 20 32 32 (20 to 62) 1:3
Limited SuS 5 5 30 (19 to 44) 1:1.5
Controls 70 70 35 (16 to 79) 1:3.4
HC 20 20 28 (24 to 50) 1:3
MS 25 25 35 (21 to 67) 1:2.6
CTD 25 25 44 (16 to 79) 1:5.3
CTD, connective tissue disorders; HC, healthy controls; MS, multiple sclerosis; n.s., not significant; SuS, Susac syndrome. aAll subjects were of Caucasian origin (SuS:
Germany (n = 20), Hungary (n = 2), Spain (n = 1), Canada (n = 1), USA (n = 1); controls: Germany). bMann Whitney U test. cFisher’s exact test. dTotal SuS group vs
controls and definite SuS subgroup vs controls.
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For evaluation of IgG subclasses, serum samples were
tested by immunohistochemistry (IHC) on mouse cerebel-
lum sections as described above, with the following modi-
fications: unconjugated sheep anti-human IgG antibodies
specific for IgG subclasses (Binding Site, Germany) were
substituted for the FITC-labeled goat anti-human IgG
antibody, and Alexa Fluor (AF) 568-labelled donkey anti-
sheep IgG (Invitrogen; absorbed against primate IgG) was
used to detect the subclass-specific antibodies. In addition,
all AECA-positive samples were tested for neuromyeli-
tis optica (NMO)-IgG/aquaporin4 (AQP4) antibodies,
the staining pattern of which shows similarities with
that of AECA when tested by IHC, using a highly
sensitive and specific commercial cell-based assay employing
recombinant human AQP4 as previously described [13-15].
In addition, double staining of monkey cerebellum sections
with a commercial antibody to AQP4, detected using
AF568-labelled anti-rabbit IgG, and sera of AECA positive
patients, detected using FITC-labeled, anti-human IgG
was performed as previously described [12].
All data were analyzed in an anonymized fashion as re-
quired by the institutional review board of the University
of Heidelberg. The Mann–Whitney U-test (2-tailed) was
used to test for significant differences between continuous
variables, and Fisher’s exact test (2-tailed) to compare pro-
portions. All tests should be understood as constituting
exploratory data analysis, such that no adjustments for
multiple testing have been made. Microsoft Excel 2003
and GraphPad Prism 4 were used for statistical analyses.
Results
Clinical and paraclinical findings
Disease onset
The median age at SuS onset was 28 years (range 17 to 56).
Signs and symptoms at disease onset included hypoacusis
in 5 patients (20%), visual disturbances in 6 (24%), and/
or signs and symptoms of encephalopathy other than
headache in 18 (72%); in none of the SuS patients wereall three predilection sites simultaneously affected at
disease onset. Fifteen patients (60%) had only enceph-
alopathic but no visual or auditory symptoms at onset.
Time to diagnosis
The time between disease onset and correct diagnosis of
SuS ranged between 0 to 126 months (median 7 months).
Diagnoses suggested at first presentation by the then treat-
ing physicians included MS (5×), ‘(chronic) inflammatory
autoimmune disorder’ (3×), ‘autoimmune demyelinating dis-
order’ (1×), ‘encephalitis’ (4×), ‘parainfectious focal encephal-
itis’ (1×), ‘encephalopathy’ (2×), ‘vasculitis’ (2×), ‘possibly
systemic lupus erythematosus’ (2×), ‘sudden acute hearing
loss’ (2×), ‘possible morbus Menière’ (1×), ‘possible Cogan
syndrome’ (1×), and ‘peripheral vertigo’ (1×).
Disease course
At the most recent follow-up (median disease duration
4.5 years, range 0 to 17), the disease had taken a relapsing
course in 19 patients (76%; median disease duration 4 years)
and was monophasic in 6 (median disease duration 4 years).
The median number of attacks at last follow-up was 3
(range 1 to 6).
Outcome
Neuropsychological symptoms, as reported by the treat-
ing physicians, were present at last follow-up in 16/25
patients (64%) and included ‘fatigue’, ‘mild psycho-organic
syndrome’, ‘disorientation’, ‘mnestic deficits’, mild to ex-
tremely severe ‘cognitive impairment’, and ‘encephalopathy’.
Motor symptoms were present in 6/25 patients (24%)
and included ‘spasticity’, ‘pyramidal signs’, ‘paresis’, ‘spastic
hemiparesis’, and ‘(spastic) tetraparesis’ (2×); sensory but
no motor symptoms (paraesthesia and hypesthesia) were
reported in 2 patients. Two patients suffered from bladder
and bowel disturbances. Three patients suffered from pos-
sible brainstem symptoms (internuclear ophthalmoplegia,
dysphagia, and mild dysarthria, respectively). Of note,
ataxia was present in 11/25 patients (44%) at most recent
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were present at last follow-up in 21/25 patients (84%),
including latent to severe, uni- or bilateral hypoacusis
and uni- or bilateral tinnitus. Scotoma was present in 18/25
patients (72%). Only one patient was free of symptoms
at last follow-up.
Ophthalmological findings
Visual disturbances occurred at least once over the course
of disease in 24/25 patients (96%; in a single patient from
the ‘limited SuS’ BRAO but no clinically apparent visual
disturbances were documented) and included scotoma in
all cases. In 22/24 cases (92%) both eyes were affected.
Fluorescein angiography was performed in 23 (96%) of the
24 patients with visual disturbances and showed BRAO in
all of them (note that BRAO were an inclusion criterion
for SuS group II, ‘limited SuS’; n = 5). The presence or ab-
sence of leakage was explicitly mentioned in 17 cases, and
leakage was present in 16 (94%). Gass plaques [16] were
present in 8/8 patients with available data.
Hearing impairment
Sensorineural hearing impairment occurred at least once
over the course of disease in 24/25 cases (96%); the only
patient without hearing impairment had bilateral tinnitus.
In at least 21/23 (91%) hearing was impaired on both sides
(side not documented in one case).
Central nervous system symptoms and magnetic resonance
imaging findings
Clinical evidence of CNS involvement was present in 22/25
patients (88%) and included motor and sensory symptoms,
brainstem symptoms, ataxia, bowel and bladder distur-
bances, neuropsychological impairment and, in one patient,
aphasia. MRI revealed callosal brain lesions in 24/25
patients (96%) on-T2 weighted imaging and in 20/24
patients (83%; no data in one patient) on T1-weighted
imaging. Periventricular T2 lesions were present in 24/25
patients (96%). Leptomeningeal enhancement was docu-
mented in five patients. All of the three patients without
clinical signs of CNS involvement had brain MRI lesions
(callosal and periventricular in two, callosal in one). Brain
atrophy as detected by MRI was noted by the attending
radiologist in 14/25 patients (56%).
Cerebrospinal fluid findings
White cell counts were mostly low (median 6.5/μl, range
0 to 42). CSF pleocytosis (≥5 cells/μl) was found in 14/22
patients at least once over the course of disease (63.6%; no
lumbar puncture (LP) performed or no data available in
the remaining three cases). Of the 24 documented lumbar
punctures (two patients had a repeat LP), 15 (62.5%)
revealed pleocytosis. The pleocytosis was generally mild
(median 12 white cells/µl, range 5 to 42).CSF protein levels were elevated in 20/25 (80%) patients.
CSF-restricted oligoclonal bands (OCB) were present only
in 3/23 patients (13%); repeat lumbar puncture was
performed in two of the initially OCB-negative patients
and was again negative for OCB. Additional, quantitative
evidence for intrathecal IgG synthesis was present in two
(OCB-positive) patients. Evidence for blood-CSF barrier
disruption as indicated by an elevated albumin CSF/serum
ratio (QAlb >Qlim(Alb) [17]) was present in seven out of
nine patients (78%). Documented QAlb values ranged be-
tween 3.4 and 67.1 (median 17.5). CSF lactate levels were
tested only in five patients and were normal in all of them.
The CSF/serum glucose ratio was lowered in 2/4 patients
(0.45 and 0.43, respectively).
Other laboratory findings
Auto-antibodies other than AECA were reported in 6/23
patients (26%; no data in 2), including anti-nuclear anti-
bodies (3×), perinuclear anti-neutrophil cytoplasmic
antibodies (1×), anti-thyroid peroxidase antibodies (1×),
anti-thyroid microsomal antibodies (1×), and anti-C1q
antibodies; in one patient, circulating immune com-
plexes were reported. One patient each was diagnosed
with IgA deficiency and activated protein C resistance,
protein S deficiency, or elevated C3c. However, in none
of the 25 SuS patients had a diagnosis of SLE or any
other connective tissue disorder been made. AECA fre-
quency and titers are reported below.
Biopsy findings
Brain biopsy was performed in two patients and showed
perivenous infiltration, focal demyelination and necrosis,
activated microglia, and reactive gliosis.
Anti-endothelial cell serum antibodies
AECA were diagnosed visually based on the typical staining
pattern; endothelial rather than perivascular astrocytic stain-
ing was confirmed in positive cases by using a commercial
anti-AQP4 antibody as previously described [9] with none
of the sera showing staining of astrocytic endfeet (Figure 1).
All AECA-positive samples were negative for NMO-IgG/
AQP4-Ab, the cerebellar staining pattern of which share
minor similarities with that of AECA, when tested using
an AQP4-specific cell based assay [13].
AECA frequency
Based on a cut-off titer of ≥1:10 (lowest dilution tested),
serum AECA were detected in 7/20 patients (35%; all
female) with definite SuS (group I) but in none of 5
patients with limited SuS (group II) (P = n.s.) (Figure 2).
Follow-up samples (n = 12) were available from 7 pa-
tients; in the only one of these patients who was AECA
seropositive, all four available follow-up samples were
positive as well, and in the remaining 6 seronegative
Figure 1 Immunohistochemical differentiation of anti-endothelial
cell antibodies (AECA) and aquaporin-4 (AQP4)-IgG by double
staining with patient serum and a commercial anti-human AQP4
antibody. While AECA (green) stain the endothelial cells, the AQP4
antibody (red) stains the astrocytic endfeet surrounding the
microvasculature.
Figure 2 Anti-endothelial cell IgG serum antibodies (AECA) in Susac syn
was used to detect binding of patient IgG to in situ primate brain endothelial
Asterisks: vessel lumen. A: Overview at 10× magnification. B: Magnification at
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AECA. Overall, 34.4% (11/32) of samples from patients
with definite SuS were positive. In the control group, 8/
70 patients (11.4%; all but one female) were positive (P
= 0.036 versus definite SuS, if only the first SuS sample
is taken into account; P = 0.012 versus definite SuS, if
also follow-up SuS samples are taken into account);
AECA were found in all three diagnostic subgroups
(MS: 4/25 (16%); CTD: 2/25 (8%); and HC: 2/20 (10%))
(Table 2).
If a more conservative cut-off of >1:100 was used,
25% (5/20) of the patients with definite SuS but only 4.3%
(3/70; 2 × RRMS, 1 × SS) of the controls were positive
for AECA (P = 0.012) and 28.1% (9/32) of the definite SuS
samples (P = 0.002) (Table 2).
Finally, the best specificity (but the lowest sensitivity)
was achieved if only titers >1:320 were considered. Titers
>1:320 were absent in all of the controls (n = 70) but
were found in 15% of the patients with definite SuSdrome. A fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG
cells (green). DAPI was used to stain cell nuclei (blue, lower right insert).
various levels (20 × to 40×).
Table 2 Frequency of anti-endothelial cell antibodies (AECA) and AECA titers in patients with Susac syndrome (SuS)
and controls according to cut-off levels
AECA, patients (%) AECA, samples (%) AECA, median titers AECA, titer ranges
AECA ≥1:10
Definite SuS 7/20 (35) P = 0.036c,d 11/32 (34) P = 0.012c,d 1:3200 1:100 – 1:17,500
Limited SuS 0/5 (0) 0/5 (0) N.a. N.a.
Controls 8/70 (11) 8/70 (11) 1:100 1:10 – 1:320
HC 2/20 (10) 2/20 (10) 1:55 1:10 – 1:100
MS 4a/25 (16) 4/25 (16) 1:210 1:10 – 1:320
CTD 2b/25 (8) 2/25 (8) 1:165 1:10 – 1:320
AECA >1:100
Definite SuS 5/20 (25) P = 0.015c,d 9/32 (28) P = 0.002c,d 1:3200 1:100 – 1:17,500
Limited SuS 0/5 (0) 0/5 (0) N.a. N.a.
Controls 3/70 (4) 3/70 (4) 1:320 1:320 – 1:320
HC 0/20 (0) 0/20 (0) N.a. N.a.
MS 2/25 (8) 2/25 (8) 1:320 1:320 – 1:320
CTD 1/25 (4) 1/25 (4) 1:320 1:320
AECA >1:320
Definite SuS 3/20 (15) P = 0.01c,d 7/32 (22) P < 0.0002c,d 1:7500 1:1000 – 1:17,500
Limited SuS 0/5 (0) 0/5 (0) N.a. N.a.
Controls 0/70 (0) 0/70 (0) N.a. N.a.
HC 0/20 (0) 0/20 (0) N.a. N.a.
MS 0/25 (0) 0/25 (0) N.a. N.a.
CTD 0/25 (0) 0/25 (0) N.a. N.a.
a3 × RRMS, 1 × PPMS. b1 × SLE, 1 × Sjögren syndrome. cFisher’s exact test. dDefinite SuS vs controls. N.a. = not applicable.
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ples (n = 32; P = 0.00018) (Table 2).AECA titers
Median AECA titers were significantly higher in samples
obtained from patients with definite SuS (1:3,200; range
100 to 17,500) than in samples obtained from controls
(median 1:100; range 1:1:10 to 1:320) (P = 0.005). As stated
above, none of the control samples yielded titers >1:320.
See Table 2 for details.IgG subclass analysis
IgG subclass analysis was performed in the five highly
AECA-positive SuS serum samples and revealed antibodies
of the strongly complement-activating IgG1 and IgG3 sub-
classes in all cases (Figure 3C) but not in five randomly
chosen control samples; additional AECA of the IgG2 and
the IgG4 subclasses were present in 5/5 and 4/5 samples,
respectively, when tested at a dilution of 1:32. Titration of
serum samples from three total IgG-AECA-positive patients
revealed IgG1-AECA titers of >1:10,000 (total-IgG-AECA:
1:17,500), 1:1,000 (total-IgG-AECA: 1:3,200), and 1:1,000
(total IgG-AECA: 1:1,000), respectively (note as a caveatthat total-IgG titers and IgG1 titers are not directly com-
parable, since different detection antibodies are used).
Anti-endothelial IgM and IgA antibodies
All IgG-AECA-positive SuS samples (n = 11) were in
addition tested for AECA of the IgA and the IgM class.
A total of 10 of these samples (90.9%), were positive for
IgA-AECA and 5 (45.5%) for IgM-AECA (Figure 3A, B).
Effect of disease activity
No association between AECA seropositivity or AECA
titers and acute disease was found in the present cohort:
While four AECA-positive SuS samples were obtained
during phases of active disease, nine AECA-positive SuS
samples (including the four samples with the highest
AECA titers (1:17,500, 1:10,000, 1:10,000, 1:7,500)) were
taken during remission.
Effect of disease duration
Median disease duration in the AECA-positive samples
was 2 years with a range of 0 to 17 years. Although a
positive correlation of AECA titers with time since on-
set in years was found (P = 0.002), this may simply reflect
the inclusion of five samples from a single patient with
Figure 3 Anti-endothelial cell antibodies (AECA) belonged to the IgG, IgA and IgM classes and included complement-activating IgG1
antibodies. A: AECA of the IgA class. B: AECA of the IgM class, C: AECA of the IgG1 subclass. Fluorescein isothiocyanate (FITC)-labeled goat anti-human
IgM or IgA antibodies (green) and a sheep anti-human IgG1 antibody (detected by means of an Alexa Fluor™568-labelled donkey anti-sheep
IgG antibody; red) were used to detect binding of patient immunoglobulin to in situ primate brain endothelial cells. See Results section for details.
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short period of time (29 months) and were all highly posi-
tive for AECA. Moreover, it is generally difficult to define
the exact time of SuS onset, since the condition can start
with non-specific neuropsychological symptoms.
Treatment effects
To evaluate whether AECA seronegativity was due to im-
munotherapy in some patients, we analyzed the patients’
treatment status at the time of blood sampling and within
12 months before blood sampling. However, the majority ofAECA-negative samples was taken during IS/IM-free inter-
vals (Table 3, row 1 to 2). Moreover, all 15 AECA-negative
untreated samples were obtained >12 months after the last
administration of an IS/IM treatment (including steroids)
or had never been treated with IS or IM drugs. On the
other hand, a more detailed analysis distinguishing between
the various IS/IM treatments used (Table 3, row 3 to 8)
showed that all samples obtained during treatment with
either azathioprine or cyclophosphamide (n = 5) were
negative for AECA. The frequency of AECA was also
lower among samples taken during steroid treatment
Table 3 Immunosuppressive and immunomodulatory
treatments at the time of blood sampling (N = 37) in
patients (N = 25) with Susac syndrome (SuS), stratified








Untreated 19 4 15
Treateda 16 6 10
Steroids 11 3 8
IVIG 6 3 4
Azathioprine 2 0 2
Cyclophosphamide 3 0 3
Mycophenolate mofetil 3 2 1
Methotrexate 1 1 0
Unknown 2 1 1
aNote that the values in rows 3 to 8 of each column do not sum up to the
values given in row 2 of the same column, since some patients received more
than immunosuppressive/immunomodulatory treatment at the time of blood
sampling. AECA, anti-endothelial cell antibodies; IVIG, intravenous
immunoglobulins; SuS, Susac syndrome.
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IS/IM could have played a role as well in the AECA-
negative steroid-treated patients (3 × cyclophosphamide,
2 × IVIG, 2 ×AZA). Among the AECA-positive samples,
six were obtained during periods of active treatment with
IS and/or IM drugs and four during treatment-free intervals
(Table 3, rows 1 to 2).
Clinical and paraclinical findings in seropositive patients
No significant clinical and paraclinical differences were
observed between AECA-positive and AECA-negative
patients (not shown). Visual disturbances were bilateral
and associated with the presence of scotomata in 6/6
seropositive patients (no exact data in one); hearing loss
was bilateral in 6/7. Encephalopathic signs and symptoms
included fatigue, cognitive/mnestic impairment, paresis,
spasticity, hypaesthesia, and ataxia. Gass plaques were
present in the single AECA-positive patient with available
data. None of the AECA-positive patients was positive for
OCBs (0/7; confirmed by a repeat LP in one) or had quanti-
tative evidence of intrathecal IgG synthesis as indicated by
an increased IgG CSF/serum ratio (0/6; no data in one).
QAlb was documented in a single AECA-positive patient
and was elevated, suggesting possible BBB damage. Three
(43%) AECA-positive patients had a history of mild CSF
pleocytosis (11 to 42 cells/μl).
Comparison with rodent tissue sections
AECA titers in the SuS group were much lower when
tested on rodent tissue in all cases (for example, sample #1:
1:10,000 on primate tissue versus 1:32 on rat tissue versusnegative on mouse tissue; sample #2: 1:7,500 versus 1:100
versus 1:32, sample #3: 1:1,000 versus 1:1,000 versus 1:32).
Moreover, using rodent tissue sections, 11 additional
control samples came up positive (titer range 1:10 to 1:320),
resulting in lower specificity.
Discussion
This is one of the largest series of patients with SuS so
far. It is a potential advantage that our data are derived
from a single series with uniform inclusion criteria. By
contrast, almost all of our previous knowledge on SuS
was based on reports of single cases and small case
series, only a few of which included more than four pa-
tients. The completeness of data provided in those re-
ports, some of which were published only in abstract
form, varied widely, as did the inclusion criteria for pa-
tients with limited SuS. We therefore applied stricter cri-
teria for the inclusion of patients with abortive SuS, all
of whom had to present with BRAO, and aimed at col-
lecting a more comprehensive and complete set of data
than in some of the previous reports.
Our study reveals a broad spectrum of neurological
signs and symptoms associated with SuS, including, in
addition to headache, motor, sensory, brainstem and
cerebellar symptoms, aphasia, and cognitive and memory
decline. In addition, all patients with SuS had periven-
tricular and/or callosal brain lesions on MRI. These
findings, the mostly relapsing course, and the occasional
presence of CSF-restricted OCB underlines the relevance
of SuS as a rare differential diagnosis of MS, especially if
disease starts with isolated encephalopathic symptoms,
which was the case in 60% of our patients. The 7-T MRI
and optical coherence tomography have recently been
shown to be of help in the differential diagnosis of MS
and SuS [6,18].
The findings that visual and hearing impairments were
bilateral in 92% and 96% of cases, respectively, that 64%
of the patients had neurological symptoms at last follow-up
and, importantly, that more than half of them exhibited
brain atrophy, despite both immunosuppressive and anti-
thrombotic treatments having been tried in most cases,
characterize SuS as a severe disease.
Importantly, from both the pathogenetic and the diag-
nostic point of view, around 30% of patients with defin-
ite SuS were positive for serum AECA. The fact that
AECA were present at high titers (up to 1:17,500) in
some of these patients and were found to belong to
the complement-activating IgG1 and Ig3 subclass in
all of them, suggests that AECA might possibly play a
role in a subset of patients with SuS. IgM antibodies,
which are considered even stronger complement acti-
vators, were present in around half of the cases. Of
note, AECA were present in all five samples obtained
from a single patient with SuS taken over a period of
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not an accidental or transitory finding.
A possible role for AECA in some patients with SuS is
further supported by the finding that median AECA titers
were significantly higher in the SuS group than in the con-
trol group. AECA titers of >1:320 were exclusively found in
patients with SuS; by contrast, they were demonstrated in
none of the 70 controls, including 25 patients with CTD.
Of special note, frequency and titers of AECA were higher
in the SuS group than in the control group despite a higher
rate of immunosuppressive treatment at the time of blood
sampling in the SuS group (neither the HC nor the MS
patients had ever received long-term IS treatment).
As AECA seronegativity was not strictly associated
with IS/IM treatment or remission, the lack of AECA
seropositivity in some patients could indicate that
1. SuS is an etiologically heterogeneous syndrome,
which is not caused by AECA in all cases; and/or
2. AECA are an optional secondary phenomenon
following endothelial damage of other origin
(for example, T cell mediated) not occurring in all
patients.
In fact, a broad range of conditions are capable of causing
microinfarctions and/or BRAO, and etiological hetero-
geneity has been demonstrated over the last few years in
a number of autoimmune CNS syndromes, such as limbic
encephalitis, subacute cerebellar degeneration, neuro-
myelitis optica (NMO) and myasthenia gravis [19-22].
Importantly, AECA were absent also in a number of
patients with active disease, demonstrating that the pres-
ence of AECA, at least in some cases, is not a conditio sine
qua non for SuS flares.
Interestingly, almost 80% of all patients with available
data showed an elevated CSF/serum albumin ratio,
which in the absence of substantial CSF flow alterations
(as seen, for example, in spinal canal stenosis) is thought
to mainly reflect blood–brain barrier dysfunction. This is
well in line with results from histopathological and oph-
thalmoscopic (fluorescein dye leakage, arterial wall pla-
ques) studies showing vascular damage in SuS.
The absence of CSF-restricted OCB in most patients
does not per se argue against SuS being an autoimmune
CNS disorder and against AECA being involved in the
pathogenesis of CNS damage, since the antibodies’ antigen
might well be on the luminal side of the endothelium and
thus directly accessible to AECA in the peripheral blood.
Similarly, autoantibodies to AQP4 in NMO are mainly
produced in the periphery [23-25]. OCBs were found to
be frequently missing also in other CNS disorders of puta-
tive autoimmune etiology [26-28].
Since publication of our index case [9], a single study
on AECA in SuS has been published, the authors of whichstrongly advocated a role of such antibodies in the patho-
genesis of the syndrome [10]. However, it is unknown
whether the antibodies detected in that study were indeed
AECA, whether they bound to brain endothelial antigens,
and whether they were specific for SuS, since only endo-
thelial cells (EC) but no control cells (as naturally included
in the tissue sections used in the present study) were used
in some of the experiments, cutaneous EC instead of brain
EC were employed, no control sera were used in the IHC
experiments, statistical significance levels were pro-
vided only for a single assay, and the histopathological
data demonstrating endothelial pathology were derived
from the only of all patients that had not been tested
for AECA. Moreover, patient numbers were relatively
low. Finally, only 5 of the 11 patients tested for AECA
had the typical triad of SuS, and MRI data, which could
have supported the diagnosis especially in the ‘limited
SuS’ cases, were not supplied.
Unless the exact role of AECA in the pathogenesis of
SuS has been better defined, we believe that the detection
of AECA alone, especially if present only at low titer, does
per se not justify B cell or antibody targeted treatments.
However, an effect of IS/IM treatment at least in a subset
of patients with SuS is suggested by a number of anecdotal
reports and small retrospective case series. It is recom-
mended that IS/IM treatment of patients with SuS should
be performed in the context of controlled clinical trials or,
at least, treatment registers in the future. Such trials or
registers should include standardized serum testing for
AECA as a prerequisite for investigating the role of AECA
as well as the effect of IS/IM treatment on AECA serosta-
tus and titers in SuS in a more definite way.
For routine autoantibody testing, many clinical laborator-
ies use mouse or rat tissue instead of primate tissue. While
rodent tissue sections are more easily available, the use of
non-primate tissue may be problematic due to interspecies
differences in antigen structure. To evaluate whether pri-
mate tissue can be replaced by rodent tissue, all SuS sam-
ples seropositive on primate tissue were tested in addition
on mouse and rat cerebellum tissue sections. Based on that
direct comparison, we recommend that future studies on
AECA in SuS using IIF should use primate tissue, which
yielded higher sensitivity, titers and specificity than rodent
tissues in the present study.
It is a potential limitation of our study that some patients
were treated with IS/IM drugs at the time of blood
sampling and that some samples were taken during pe-
riods of clinical remission. However, as mentioned
above, AECA were negative also in a relevant number
of samples taken from untreated patients or taken during
active disease. Moreover, several of our AECA-positive pa-
tients had very high titers also during remission (similarly,
autoantibodies remain detectable during remission in many
neurological and non-neurological autoimmune disorders
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[30] or SLE [31]. These findings suggest that treatment and
disease activity are not the only factor determining AECA
serostatus; instead, AECA may be truly absent in some
cases of SuS as discussed above.
In summary, our study provides systematic clinical
and paraclinical information derived from a single large
series of patients with SuS. In addition, we demonstrate
that complement-activating IgG1 and IgM AECA are
present in a subset of patients with definite SuS, in some
cases at high level. Future studies are now warranted to
evaluate the exact pathogenic impact of AECA in SuS
and to identify their antigenic target.
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